• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Myelofibrosis - Pipeline Review, Q4 2010

  • ID: 1474128
  • December 2010
  • 38 pages
  • Global Markets Direct

Myelofibrosis - Pipeline Review, Q4 2010


Global Markets Direct’s, “Myelofibrosis Pipeline Review, Q4 2010”, provides an overview of the Myelofibrosis therapeutic pipeline. This report provides information on the therapeutic development for Myelofibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelofibrosis. “Myelofibrosis-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.


- A snapshot of the global therapeutic scenario for Myelofibrosis.
- A review of the Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from READ MORE >

Note: Product cover images may vary from those shown

List of Tables
List of Figures
Global Markets Direct Report Coverage
Myelofibrosis Overview
Therapeutics Development
An Overview of Pipeline Products for Myelofibrosis
Myelofibrosis Therapeutics under Development by Companies
Myelofibrosis Therapeutics under Investigation by Universities/Institutes
Companies Involved in Myelofibrosis Therapeutics Development
YM BioSciences Inc.
Novartis AG
Cephalon, Inc.
Celgene Corporation
Incyte Corporation
Threshold Pharmaceuticals, Inc.
S-BIO Pte Ltd
Gemin X Pharmaceuticals
Universities/Institutes Involved in Myelofibrosis Therapeutics Development
Myelofibrosis Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Actimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB18424 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Campath - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myelofibrosis - Featured News
Dec 06, 2010: YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response From Phase I/II Trial Of CYT387
Nov 18, 2010: YM BioSciences Expands Phase I/II Trial For JAK Inhibitor CYT387 In Patients With Myelofibrosis
Nov 08, 2010: YM BioSciences Reports Significant Response Rates In Anemia, Splenomegaly And Constitutional Symptoms From Phase I/II Trial Of CYT387 In Myelofibrosis
Oct 18, 2010: S-BIO's SB1518 Receives Orphan Drug Designation From European Commission For Treatment Of Myelofibrosis
Oct 01, 2010: YM Biosciences To Present Poster On CYT387 At European School Of Haematology International Conference
Sep 15, 2010: Incyte Announces Publication Of INCB18424 Phase I/II Study Results For Treatment Of Myelofibrosis In New England Journal Of Medicine
Aug 10, 2010: YM BioSciences Receives FDA Orphan Drug Designation For CYT387 For Treatment Of Myelofibrosis
Jun 13, 2010: S-BIO Presents Positive Safety And Tolerability Results For Its Novel Oral JAK2 Inhibitor SB1518 From A Phase I/II Study For The Treatment Of Myelofibrosis (MF)
Jun 09, 2010: S-BIO Completes Enrollment of Patients in Phase II Clinical Trials for its JAK2 Inhibitor SB1518
Jan 06, 2009: Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors from S-BIO
Secondary Research
Primary Research
Expert Panel Validation
Contact Us

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Pfizer, Inc. Grünenthal GmbH GlaxoSmithKline PLC Abbott Laboratories Ltd. Roche Diagnostics Ltd. Novo Nordisk A/S